logo
  

Merck: Interim Analysis, Additional Analyses Support Efficacy Of Molnupiravir

Merck (MRK) and Ridgeback Biotherapeutics issued an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine for COVID-19. In the study, Molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group to 6.8% in the molnupiravir group. Nine deaths were reported in the placebo group, and one in the molnupiravir group.

The companies stated that the interim analysis and the additional analyses support the efficacy and overall favorable benefit-risk assessment of molnupiravir for the treatment of mild to moderate COVID-19 in adults at high risk for disease progression. Merck will present these additional analyses to the FDA's Antimicrobial Drugs Advisory Committee on November 30.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The TJX Companies, Inc. (TJX) said its first-quarter pretax profit margin and earnings per share, each on an adjusted basis, exceeded its plans even though sales were slightly below planned range. Adjusted pretax margin was 9.4%, excluding a 1.9 percentage point charge related to a write-down of the... Apple Inc. is delaying its latest plan to ask employees to come back to the office three days a week, but will continue with its plan of two days in office a week, Bloomberg reported. Citing an internal memo, the report also said the tech major is again requiring its staff to wear masks in common spaces, meeting rooms, hallways, and elevators, as well as at 100 US stores. The U.S. Food and Drug Administration or FDA has urged infant formula manufacturers to import infant formula products to the United States to meet the ongoing severe supply shortage. In order to further increase the availability of infant formula in the country, while protecting the health of infants, the regulator announced a guidance outlining increased flexibilities for the global manufacturers
Follow RTT